$BCLI
Brainstorm Cell Therapeutics Inc

2021 Q4 Form 10-Q Financial Statement

#000110465921138505 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.535M $1.659M $2.620M
YoY Change -5.06% -36.68% 70.13%
% of Gross Profit
Research & Development $3.677M $3.618M $1.867M
YoY Change -58.31% 93.79% -53.42%
% of Gross Profit
Depreciation & Amortization $70.00K $67.00K $56.00K
YoY Change 16.67% 19.64% 51.35%
% of Gross Profit
Operating Expenses $6.212M $3.618M $1.867M
YoY Change -45.94% 93.79% -53.42%
Operating Profit -$5.277M -$4.485M
YoY Change 17.66% -19.2%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $22.00K -$59.00K $0.00
YoY Change -106.88% -100.0%
Pretax Income -$6.190M -$5.336M -$4.490M
YoY Change -47.63% 18.84% -20.25%
Income Tax
% Of Pretax Income
Net Earnings -$6.190M -$5.336M -$4.488M
YoY Change -47.63% 18.89% -20.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.15
Diluted Earnings Per Share -$170.5K -$147.0K -$144.1K
COMMON SHARES
Basic Shares Outstanding 36.28M 36.30M 31.15M
Diluted Shares Outstanding 36.30M 31.15M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.09M $27.81M $28.81M
YoY Change -47.32% -3.47% 1252.58%
Cash & Equivalents $18.86M $25.70M $24.77M
Short-Term Investments $3.238M $2.114M $4.040M
Other Short-Term Assets $1.100M $50.00K $60.00K
YoY Change 10.0% -16.67% -90.32%
Inventory
Prepaid Expenses
Receivables $86.00K $85.00K $1.470M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $23.28M $27.94M $30.34M
YoY Change -46.16% -7.89% 549.61%
LONG-TERM ASSETS
Property, Plant & Equipment $1.189M $1.224M $950.0K
YoY Change 6.26% 28.84% -69.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.997M $6.594M $2.354M
YoY Change -25.2% 180.12% 7746.67%
Total Long-Term Assets $5.997M $6.594M $2.354M
YoY Change -25.2% 180.12% -25.03%
TOTAL ASSETS
Total Short-Term Assets $23.28M $27.94M $30.34M
Total Long-Term Assets $5.997M $6.594M $2.354M
Total Assets $29.28M $34.54M $32.69M
YoY Change -42.88% 5.65% 318.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.700M $2.739M $3.283M
YoY Change -31.7% -16.57% -64.08%
Accrued Expenses $83.00K $387.0K $917.0K
YoY Change -93.42% -57.8% -53.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.317M $5.846M $6.429M
YoY Change -43.76% -9.07% -46.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.618M $3.766M $280.0K
YoY Change -20.66% 1245.0% -89.35%
Total Long-Term Liabilities $3.618M $3.766M $284.0K
YoY Change -20.69% 1226.06% -89.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.317M $5.846M $6.429M
Total Long-Term Liabilities $3.618M $3.766M $284.0K
Total Liabilities $9.935M $9.612M $6.713M
YoY Change -37.1% 43.18% -53.99%
SHAREHOLDERS EQUITY
Retained Earnings -$173.5M -$167.0M -$137.3M
YoY Change 16.4% 21.66%
Common Stock $193.0M $192.4M $163.3M
YoY Change 4.51% 17.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $19.34M $24.93M $25.98M
YoY Change
Total Liabilities & Shareholders Equity $29.28M $34.54M $32.69M
YoY Change -42.88% 5.65% 318.58%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$6.190M -$5.336M -$4.488M
YoY Change -47.63% 18.89% -20.34%
Depreciation, Depletion And Amortization $70.00K $67.00K $56.00K
YoY Change 16.67% 19.64% 51.35%
Cash From Operating Activities -$5.508M -$6.460M -$6.924M
YoY Change -27.24% -6.7% 90.95%
INVESTING ACTIVITIES
Capital Expenditures -$35.00K $237.0K $88.00K
YoY Change -84.78% 169.32% -13.73%
Acquisitions
YoY Change
Other Investing Activities -$1.262M $1.933M $0.00
YoY Change 2003.33% -100.0%
Cash From Investing Activities -$1.297M $1.696M -$86.00K
YoY Change 332.33% -2072.09% -105.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -34.00K -106.0K 19.63M
YoY Change -100.16% -100.54% 521.89%
NET CHANGE
Cash From Operating Activities -5.508M -6.460M -6.924M
Cash From Investing Activities -1.297M 1.696M -86.00K
Cash From Financing Activities -34.00K -106.0K 19.63M
Net Change In Cash -6.839M -4.870M 12.62M
YoY Change -152.33% -138.6% 1202.06%
FREE CASH FLOW
Cash From Operating Activities -$5.508M -$6.460M -$6.924M
Capital Expenditures -$35.00K $237.0K $88.00K
Free Cash Flow -$5.473M -$6.697M -$7.012M
YoY Change -25.44% -4.49% 88.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.51
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.70
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.15
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.14
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36140130
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28695540
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36304878
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31154101
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36277953
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35159977
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36277953
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25695000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37829000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
2114000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
4107000
CY2021Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
85000
CY2020Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
304000
CY2020Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
26000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5338000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6872000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1224000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1119000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6594000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
50000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1002000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
27944000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
43242000
CY2021Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8017000
CY2021Q3 us-gaap Assets
Assets
34538000
CY2020Q4 us-gaap Assets
Assets
51259000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2739000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5417000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
387000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1261000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1735000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2655000
CY2021Q3 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
985000
CY2020Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1900000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5846000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11233000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3766000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4562000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3766000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4562000
CY2021Q3 us-gaap Liabilities
Liabilities
9612000
CY2020Q4 us-gaap Liabilities
Liabilities
15795000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36277953
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35159977
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192384000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
184655000
CY2021Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167354000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149087000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
24926000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34538000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51259000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11558000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13509000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3618000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1867000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4485000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-60000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20193000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-197000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6769000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6684000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1659000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2618000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18327000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8114000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9011000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5277000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
791000
CY2020Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7411000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7394000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9822000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1017000
CY2020Q3 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
13307000
CY2021Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
59000
CY2020Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
3000
us-gaap Net Income Loss
NetIncomeLoss
-18267000
us-gaap Net Income Loss
NetIncomeLoss
-19996000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5336000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4488000
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.51
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.70
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.15
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.14
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36140130
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28695540
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36304878
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31154101
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
390000
CY2020Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
18972000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000
CY2020Q3 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6300000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4488000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
25978000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
290000
CY2021Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7104000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6662000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36201000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
240000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
196000
CY2021Q3 bcli Issuance Costs Related To At Market Offering
IssuanceCostsRelatedToAtMarketOffering
-106000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5336000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
24926000
us-gaap Profit Loss
ProfitLoss
-18267000
us-gaap Profit Loss
ProfitLoss
-19996000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5336000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-4488000
us-gaap Depreciation
Depreciation
190000
us-gaap Depreciation
Depreciation
155000
CY2021Q3 us-gaap Depreciation
Depreciation
67000
CY2020Q3 us-gaap Depreciation
Depreciation
56000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
726000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2198000
CY2021Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
196000
CY2020Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1017000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-182000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-61000
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
8000
CY2020Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-11000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1243000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1267000
CY2021Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-516000
CY2020Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
1095000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2678000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-11394000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-261000
CY2020Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1321000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1789000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
216000
CY2021Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1650000
CY2020Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1082000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20757000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27615000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6460000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6924000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
295000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
88000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1915000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
4005000
CY2021Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1933000
CY2020Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1620000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4150000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1696000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
bcli Proceeds From At Market
ProceedsFromAtMarket
6998000
bcli Proceeds From At Market
ProceedsFromAtMarket
39690000
CY2021Q3 bcli Proceeds From At Market
ProceedsFromAtMarket
-106000
CY2020Q3 bcli Proceeds From At Market
ProceedsFromAtMarket
13307000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9957000
bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
6300000
CY2020Q3 bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
6300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7003000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55999000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-106000
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19627000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12134000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24234000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4870000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12617000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25695000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24770000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25695000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24770000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
CY2020 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
CY2021Q3 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
0
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
984000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5338000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5501000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
690000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y7M13D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0683
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1783000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1071000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1418000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1378000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
229000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5879000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
378000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
5501000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151000000
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3522421
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
726000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2198000
us-gaap Share Based Compensation
ShareBasedCompensation
726000
us-gaap Share Based Compensation
ShareBasedCompensation
2198000
CY2021Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
12222000
CY2020Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
17146000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11558000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13509000

Files In Submission

Name View Source Status
0001104659-21-138505-index-headers.html Edgar Link pending
0001104659-21-138505-index.html Edgar Link pending
0001104659-21-138505.txt Edgar Link pending
0001104659-21-138505-xbrl.zip Edgar Link pending
bcli-20211030.xsd Edgar Link pending
bcli-20211030x10q.htm Edgar Link pending
bcli-20211030x10q_htm.xml Edgar Link completed
bcli-20211030xex10d1.htm Edgar Link pending
bcli-20211030xex31d1.htm Edgar Link pending
bcli-20211030xex31d2.htm Edgar Link pending
bcli-20211030xex32d1.htm Edgar Link pending
bcli-20211030xex32d2.htm Edgar Link pending
bcli-20211030_cal.xml Edgar Link unprocessable
bcli-20211030_def.xml Edgar Link unprocessable
bcli-20211030_lab.xml Edgar Link unprocessable
bcli-20211030_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending